Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Women's Health | 14 | 2021 | 178 | 1.720 |
Why?
|
| Metabolic Syndrome | 6 | 2020 | 55 | 1.660 |
Why?
|
| Menopause | 9 | 2021 | 94 | 1.470 |
Why?
|
| Adiposity | 8 | 2018 | 38 | 1.460 |
Why?
|
| Intra-Abdominal Fat | 6 | 2021 | 39 | 1.270 |
Why?
|
| Obesity | 6 | 2018 | 277 | 1.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2015 | 173 | 1.060 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 333 | 1.000 |
Why?
|
| Ecosystem | 1 | 2023 | 22 | 0.880 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 126 | 0.880 |
Why?
|
| Middle Aged | 36 | 2021 | 8511 | 0.870 |
Why?
|
| Thrombosis | 2 | 2014 | 51 | 0.830 |
Why?
|
| Obesity, Abdominal | 4 | 2015 | 19 | 0.800 |
Why?
|
| Female | 43 | 2021 | 14411 | 0.750 |
Why?
|
| Atrial Fibrillation | 2 | 2014 | 132 | 0.730 |
Why?
|
| Adrenal Gland Diseases | 2 | 2012 | 3 | 0.730 |
Why?
|
| Abdominal Fat | 3 | 2021 | 8 | 0.650 |
Why?
|
| Humans | 47 | 2023 | 26049 | 0.640 |
Why?
|
| Diet Therapy | 1 | 2018 | 10 | 0.630 |
Why?
|
| Weight Reduction Programs | 1 | 2018 | 22 | 0.610 |
Why?
|
| Risk Factors | 20 | 2021 | 2246 | 0.610 |
Why?
|
| Atherosclerosis | 3 | 2021 | 50 | 0.590 |
Why?
|
| Behavior Therapy | 1 | 2018 | 81 | 0.590 |
Why?
|
| Exercise Therapy | 1 | 2018 | 95 | 0.580 |
Why?
|
| Adult | 22 | 2021 | 7367 | 0.580 |
Why?
|
| Hydrocortisone | 3 | 2012 | 38 | 0.570 |
Why?
|
| United States | 15 | 2021 | 1981 | 0.570 |
Why?
|
| Testosterone | 2 | 2014 | 26 | 0.560 |
Why?
|
| Waist-Height Ratio | 1 | 2016 | 5 | 0.550 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 10 | 0.550 |
Why?
|
| Mass Screening | 1 | 2016 | 166 | 0.490 |
Why?
|
| Cognition Disorders | 2 | 2020 | 991 | 0.470 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 39 | 0.450 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 10 | 0.430 |
Why?
|
| Prevalence | 4 | 2016 | 433 | 0.420 |
Why?
|
| Adrenal Cortex Function Tests | 1 | 2012 | 1 | 0.420 |
Why?
|
| Hemodynamics | 1 | 2012 | 61 | 0.410 |
Why?
|
| Liver Cirrhosis | 1 | 2012 | 42 | 0.400 |
Why?
|
| Postmenopause | 6 | 2019 | 49 | 0.400 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2009 | 7 | 0.400 |
Why?
|
| Lipoproteins, HDL | 3 | 2014 | 21 | 0.390 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2009 | 2 | 0.390 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2021 | 15 | 0.380 |
Why?
|
| Biomarkers | 5 | 2020 | 551 | 0.380 |
Why?
|
| Perimenopause | 3 | 2021 | 14 | 0.370 |
Why?
|
| Longitudinal Studies | 9 | 2020 | 1344 | 0.370 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 1713 | 0.360 |
Why?
|
| Diastole | 1 | 2010 | 28 | 0.340 |
Why?
|
| Absorptiometry, Photon | 3 | 2015 | 78 | 0.340 |
Why?
|
| Adrenal Insufficiency | 1 | 2009 | 6 | 0.340 |
Why?
|
| Blood Glucose | 5 | 2020 | 99 | 0.340 |
Why?
|
| Cardiomyopathies | 1 | 2010 | 32 | 0.340 |
Why?
|
| Vitamin D | 1 | 2010 | 38 | 0.330 |
Why?
|
| Reproducibility of Results | 4 | 2014 | 670 | 0.320 |
Why?
|
| Pituitary Diseases | 1 | 2008 | 3 | 0.310 |
Why?
|
| Hypothalamic Diseases | 1 | 2008 | 8 | 0.310 |
Why?
|
| Algorithms | 3 | 2023 | 358 | 0.310 |
Why?
|
| Hypertension | 4 | 2021 | 217 | 0.310 |
Why?
|
| Body Mass Index | 5 | 2018 | 412 | 0.300 |
Why?
|
| Socioeconomic Factors | 4 | 2023 | 290 | 0.290 |
Why?
|
| Depression | 3 | 2018 | 408 | 0.290 |
Why?
|
| Prospective Studies | 6 | 2020 | 1663 | 0.290 |
Why?
|
| Population Surveillance | 2 | 2020 | 101 | 0.280 |
Why?
|
| Cohort Studies | 7 | 2020 | 1829 | 0.270 |
Why?
|
| Exercise | 3 | 2018 | 450 | 0.270 |
Why?
|
| Male | 13 | 2020 | 14025 | 0.270 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 485 | 0.270 |
Why?
|
| Prognosis | 3 | 2020 | 750 | 0.270 |
Why?
|
| Risk Assessment | 3 | 2020 | 622 | 0.270 |
Why?
|
| Ketone Bodies | 1 | 2005 | 4 | 0.250 |
Why?
|
| Incidence | 5 | 2020 | 714 | 0.250 |
Why?
|
| ROC Curve | 3 | 2009 | 132 | 0.240 |
Why?
|
| Insulin | 2 | 2011 | 76 | 0.230 |
Why?
|
| Economic Development | 1 | 2023 | 3 | 0.230 |
Why?
|
| Estradiol | 4 | 2021 | 37 | 0.230 |
Why?
|
| Diet | 2 | 2019 | 171 | 0.230 |
Why?
|
| Developing Countries | 1 | 2023 | 12 | 0.230 |
Why?
|
| Chicago | 5 | 2014 | 845 | 0.230 |
Why?
|
| Pregnanediol | 2 | 2021 | 7 | 0.220 |
Why?
|
| Luteinizing Hormone | 2 | 2021 | 9 | 0.220 |
Why?
|
| Pharmacoepidemiology | 2 | 2020 | 4 | 0.220 |
Why?
|
| Life Style | 2 | 2018 | 187 | 0.220 |
Why?
|
| Energy Intake | 3 | 2019 | 71 | 0.210 |
Why?
|
| Atrial Appendage | 2 | 2014 | 36 | 0.210 |
Why?
|
| Hypoglycemic Agents | 1 | 2003 | 33 | 0.210 |
Why?
|
| Energy Metabolism | 2 | 2018 | 32 | 0.210 |
Why?
|
| Aged | 11 | 2020 | 8719 | 0.210 |
Why?
|
| Waist Circumference | 4 | 2016 | 31 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 275 | 0.200 |
Why?
|
| Stroke Volume | 2 | 2014 | 55 | 0.200 |
Why?
|
| Hyperglycemia | 2 | 2020 | 28 | 0.190 |
Why?
|
| Menstrual Cycle | 2 | 2021 | 16 | 0.190 |
Why?
|
| Progesterone | 1 | 2021 | 11 | 0.190 |
Why?
|
| Carotid Artery Diseases | 1 | 2021 | 15 | 0.180 |
Why?
|
| Cosyntropin | 2 | 2012 | 3 | 0.180 |
Why?
|
| Multimorbidity | 1 | 2020 | 7 | 0.180 |
Why?
|
| Insulin Resistance | 4 | 2011 | 45 | 0.180 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 90 | 0.170 |
Why?
|
| Cholesterol, HDL | 3 | 2011 | 23 | 0.170 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 43 | 0.170 |
Why?
|
| Cerebral Hemorrhage | 1 | 2020 | 106 | 0.170 |
Why?
|
| Seasons | 1 | 2019 | 21 | 0.160 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 93 | 0.160 |
Why?
|
| Appetite | 1 | 2018 | 4 | 0.160 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 70 | 0.160 |
Why?
|
| Chronic Disease | 1 | 2020 | 416 | 0.150 |
Why?
|
| Weight Gain | 1 | 2018 | 61 | 0.150 |
Why?
|
| Fractures, Bone | 1 | 2019 | 75 | 0.150 |
Why?
|
| Body Weight | 1 | 2018 | 121 | 0.150 |
Why?
|
| Time Factors | 4 | 2020 | 1364 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 373 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 102 | 0.150 |
Why?
|
| Weight Loss | 1 | 2018 | 120 | 0.140 |
Why?
|
| Hormones | 1 | 2017 | 8 | 0.140 |
Why?
|
| Depressive Disorder | 1 | 2018 | 167 | 0.140 |
Why?
|
| Social Support | 1 | 2018 | 182 | 0.140 |
Why?
|
| Beverages | 1 | 2016 | 7 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 457 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2014 | 3305 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2009 | 853 | 0.130 |
Why?
|
| Child | 3 | 2009 | 1229 | 0.130 |
Why?
|
| Climacteric | 1 | 2015 | 4 | 0.130 |
Why?
|
| Estrogens | 1 | 2015 | 25 | 0.130 |
Why?
|
| False Positive Reactions | 1 | 2015 | 32 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 14 | 0.120 |
Why?
|
| Immunoassay | 1 | 2015 | 37 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 713 | 0.120 |
Why?
|
| Age Factors | 3 | 2020 | 744 | 0.120 |
Why?
|
| Carbonated Beverages | 1 | 2014 | 2 | 0.120 |
Why?
|
| Research Report | 1 | 2014 | 7 | 0.120 |
Why?
|
| Sweetening Agents | 1 | 2014 | 6 | 0.120 |
Why?
|
| Waist-Hip Ratio | 1 | 2014 | 12 | 0.120 |
Why?
|
| Meals | 1 | 2014 | 10 | 0.120 |
Why?
|
| Birth Weight | 1 | 2015 | 43 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2015 | 28 | 0.120 |
Why?
|
| Illinois | 2 | 2013 | 227 | 0.120 |
Why?
|
| Oligomenorrhea | 1 | 2014 | 1 | 0.110 |
Why?
|
| Hyperandrogenism | 1 | 2014 | 1 | 0.110 |
Why?
|
| Self Report | 3 | 2020 | 203 | 0.110 |
Why?
|
| Personal Satisfaction | 1 | 2014 | 40 | 0.110 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2014 | 36 | 0.110 |
Why?
|
| Body Image | 1 | 2014 | 25 | 0.110 |
Why?
|
| Employment | 1 | 2013 | 40 | 0.110 |
Why?
|
| Heart Valve Diseases | 1 | 2013 | 16 | 0.110 |
Why?
|
| Body Fat Distribution | 1 | 2012 | 11 | 0.100 |
Why?
|
| Motor Activity | 2 | 2018 | 314 | 0.100 |
Why?
|
| Blood Pressure | 4 | 2019 | 194 | 0.100 |
Why?
|
| Logistic Models | 3 | 2019 | 362 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 161 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2012 | 151 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 1026 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 327 | 0.100 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 1228 | 0.090 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2011 | 2 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2013 | 222 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 353 | 0.090 |
Why?
|
| Calcifediol | 1 | 2010 | 2 | 0.090 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2010 | 2 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2009 | 589 | 0.090 |
Why?
|
| Infant | 2 | 2009 | 522 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 4674 | 0.090 |
Why?
|
| Pericardium | 1 | 2010 | 18 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 40 | 0.090 |
Why?
|
| Metyrapone | 1 | 2009 | 1 | 0.090 |
Why?
|
| Particle Size | 1 | 2010 | 51 | 0.090 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 13 | 0.090 |
Why?
|
| Reference Standards | 1 | 2009 | 23 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 68 | 0.080 |
Why?
|
| Antimetabolites | 1 | 2009 | 13 | 0.080 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2021 | 17 | 0.080 |
Why?
|
| Hospitals, Public | 1 | 2009 | 25 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2010 | 253 | 0.080 |
Why?
|
| Health Behavior | 1 | 2010 | 153 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 930 | 0.080 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2008 | 11 | 0.080 |
Why?
|
| Fasting | 1 | 2008 | 13 | 0.080 |
Why?
|
| Urban Population | 1 | 2009 | 143 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2008 | 62 | 0.070 |
Why?
|
| Hypercalcemia | 1 | 2007 | 10 | 0.070 |
Why?
|
| Burns | 1 | 2007 | 19 | 0.070 |
Why?
|
| Carotid Arteries | 2 | 2021 | 13 | 0.070 |
Why?
|
| Adolescent | 2 | 2009 | 2064 | 0.070 |
Why?
|
| Linear Models | 2 | 2018 | 240 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 140 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 166 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2007 | 279 | 0.060 |
Why?
|
| Lamin Type A | 1 | 2004 | 1 | 0.060 |
Why?
|
| Lipodystrophy | 1 | 2004 | 1 | 0.060 |
Why?
|
| Acyltransferases | 1 | 2004 | 3 | 0.060 |
Why?
|
| GTP-Binding Protein gamma Subunits | 1 | 2004 | 2 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 53 | 0.060 |
Why?
|
| Young Adult | 1 | 2009 | 1853 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2015 | 260 | 0.060 |
Why?
|
| Gluconeogenesis | 1 | 2003 | 3 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2003 | 4 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 14 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2003 | 36 | 0.050 |
Why?
|
| Triglycerides | 2 | 2014 | 40 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2014 | 304 | 0.050 |
Why?
|
| Liver | 1 | 2003 | 123 | 0.050 |
Why?
|
| Ankle Brachial Index | 1 | 2021 | 2 | 0.050 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 4 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2015 | 1066 | 0.050 |
Why?
|
| Patient Selection | 1 | 2003 | 193 | 0.050 |
Why?
|
| Vasomotor System | 1 | 2021 | 2 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 291 | 0.050 |
Why?
|
| Cognition | 1 | 2009 | 1301 | 0.050 |
Why?
|
| Affect | 1 | 2021 | 53 | 0.050 |
Why?
|
| Disease Progression | 1 | 2003 | 685 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 55 | 0.040 |
Why?
|
| Hypertriglyceridemia | 2 | 2014 | 13 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2019 | 19 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 31 | 0.040 |
Why?
|
| Healthy Aging | 1 | 2018 | 15 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2018 | 52 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2019 | 77 | 0.040 |
Why?
|
| Hospitalization | 1 | 2020 | 294 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2018 | 253 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2019 | 113 | 0.040 |
Why?
|
| Sleep | 1 | 2020 | 255 | 0.040 |
Why?
|
| Estrone | 1 | 2017 | 8 | 0.040 |
Why?
|
| Corpus Luteum | 1 | 2017 | 5 | 0.040 |
Why?
|
| Premenopause | 1 | 2017 | 10 | 0.040 |
Why?
|
| Genotype | 1 | 2018 | 336 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 284 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 22 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 21 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 2 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 58 | 0.030 |
Why?
|
| Androgens | 1 | 2014 | 7 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 295 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 550 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 134 | 0.030 |
Why?
|
| Tunica Intima | 1 | 2011 | 9 | 0.020 |
Why?
|
| Stroke | 1 | 2014 | 254 | 0.020 |
Why?
|
| Nutrition Policy | 1 | 2010 | 6 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2010 | 19 | 0.020 |
Why?
|
| France | 1 | 2010 | 19 | 0.020 |
Why?
|
| Vegetables | 1 | 2010 | 18 | 0.020 |
Why?
|
| Fruit | 1 | 2010 | 22 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 52 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2010 | 36 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2009 | 14 | 0.020 |
Why?
|
| Biological Availability | 1 | 2009 | 19 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 216 | 0.020 |
Why?
|
| Aging | 1 | 2018 | 1540 | 0.020 |
Why?
|
| Albumins | 1 | 2007 | 18 | 0.020 |
Why?
|
| Knowledge | 1 | 2007 | 14 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 25 | 0.020 |
Why?
|
| Lipids | 1 | 2007 | 28 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 3293 | 0.020 |
Why?
|
| Length of Stay | 1 | 2007 | 302 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2004 | 7 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2004 | 7 | 0.010 |
Why?
|
| 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2004 | 1 | 0.010 |
Why?
|
| Hyperinsulinism | 1 | 2004 | 3 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2004 | 3 | 0.010 |
Why?
|
| RNA Splice Sites | 1 | 2004 | 2 | 0.010 |
Why?
|
| Consanguinity | 1 | 2004 | 6 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 34 | 0.010 |
Why?
|
| Exons | 1 | 2004 | 30 | 0.010 |
Why?
|
| Homozygote | 1 | 2004 | 19 | 0.010 |
Why?
|
| Calcium | 1 | 2007 | 368 | 0.010 |
Why?
|
| Haplotypes | 1 | 2004 | 55 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 202 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 291 | 0.010 |
Why?
|